May 01, 2026
Life Science Magazines About Us Contact Us
Life Science Newswire Service™ (LS)
Submit a Press Release
  • Analytical chemistry
  • Business
  • Biomanufacturing & bioprocessing
  • Biotechnology
  • Diagnostics
  • Drug development
  • More News
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • Press Releases
Reading: Focus on Fintiv: Shift in Patent Office Guidance for Discretionary Denials of Patent Challenges
Share
Font ResizerAa
Life Science Newswire Service™ (LS)Life Science Newswire Service™ (LS)
Search
  • Business
  • Press Releases
  • Life Science Magazines
  • Life Sciences
    • Analytical chemistry
    • Biomanufacturing & bioprocessing
    • Biotechnology
    • Diagnostics
    • Drug development
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • About Us
  • Contact Us
  • Submit a Press Release
LS Newswire Service™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Life Science Newswire Service™ (LS) > Blog > Life Sciences > Biotechnology > Focus on Fintiv: Shift in Patent Office Guidance for Discretionary Denials of Patent Challenges
Biotechnology

Focus on Fintiv: Shift in Patent Office Guidance for Discretionary Denials of Patent Challenges

By Newsroom
Last updated: April 5, 2025
1 Min Read
Share


On February 28, 2025, the U.S. Patent and Trademark Office announced that it was rescinding a 2022 memorandum that provided guidance regarding the application of the Apple v. Fintiv decision to the Patent Trial and Appeal Board’s discretion to deny patent challenges with pending parallel district court litigation. The PTO has referred parties back to precedent for guidance including Apple Inc. v. Fintiv, Inc. Rescinding the 2022 memorandum also has the effect of effectively removing the proposed rules related to discretionary denial that were under consideration as recently as last year.

35 U.S.C. § 314(a) provides the…



Source link

Share This Article
Facebook Email Copy Link Print

HOT NEWS

First Quarterly Stormwater Sampling Deadline of 2025 Approaching

Environmental Science
April 5, 2025

Radiopharmaceuticals: A Wall Street Perspective on Value and…

Commercial success of radiopharmaceuticals depends on how well therapies align with real-world care delivery. From…

May 1, 2026

تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك

California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…

April 5, 2025

Arab Newswire Provides Press Release Distribution in Arabic

Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…

April 5, 2025

YOU MAY ALSO LIKE

Impact of the Leadership in Critical Technologies Act on U.S. Artificial Intelligence, Semiconductors and Quantum Computing

On the heels of the recent reintroduction of the PERA and PREVAIL Acts of 2025, a bipartisan group of lawmakers…

Biotechnology
June 13, 2025

PTO Defends its Recent Policy Changes Regarding Discretionary Denials

In the past few months, the U.S. Patent and Trademark Office (“PTO”) Acting Director has made substantial changes to the…

Biotechnology
December 28, 2025

FDA Proposes Risk-Based and Remote Inspection Strategies in New Report

On May 5, 2021, the U.S. Food and Drug Administration (FDA) issued a much-anticipated report, “Resiliency Roadmap for FDA Inspectional…

Biotechnology
April 5, 2025

Value and Risk of Overlapping Intellectual Property Protections

A well-orchestrated intellectual property strategy requires carefully and thoughtfully leveraging copyright, trademark, and patent laws, as highlighted by a recent…

Biotechnology
May 16, 2025
Life Science Newswire Service™ (LS)

Contact Us

  • Whatsapp: +1 832-716-2363
  • Skype: Groupwebmedia
  • Telegram: Groupwebmedia

Share Us

About Us

Life Science Newswire Services (LS)™ aggregates, publishes and distributed news about the Life Science industry. In association with EmailWire, LS provides press release distribution services in the Life Science sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us.

Categories

Analytical chemistry
Business
Biomanufacturing & bioprocessing
Biotechnology
Diagnostics
Drug development
Environmental Science
Food & beverage
Forensic science
Healthcare
Hospitals
Lab tools
Materials science
Microbiology
Nanotechnology
Pharma & Biopharma
Pharmacy
Veterinary
Water Management
Life Science Magazines
Press Releases

Recent News

Radiopharmaceuticals: A Wall Street Perspective on Value and…
May 1, 2026
Managing Operational Complexity in Early-Phase Oncology…
May 1, 2026
Revolutionizing Drug Discovery From Undruggables To AI
May 1, 2026
Cost And Scalability Key Drivers Of Expanded Gene Therapy…
May 1, 2026

Life Science Magazines

Radiopharmaceuticals: A Wall Street Perspective on Value and…
May 1, 2026
Managing Operational Complexity in Early-Phase Oncology…
May 1, 2026
Revolutionizing Drug Discovery From Undruggables To AI
May 1, 2026
Cost And Scalability Key Drivers Of Expanded Gene Therapy…
May 1, 2026

LS Newswire Service™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?